Vytorin Side Effects May Result In Clogged Arteries Lawsuits
Vytorin Side Effects Injury Lawsuits. On January 14, 2008, the results of a long-awaited study on the effectiveness of Vytorin to reduce artery clogging plaque in patients with high cholesterol were released. The ENHANCE study found that Vytorin, a combination of cholesterol lowering Zetia and the statin Zocor, worked no … [Read more...]
Vytorin Makers $41.5M Settlement
Vytorin Makers Class Action Settlement. Vytorin is a combination of Zetia and the statin Zocor. It has been under the microscope since the ENHANCE study was released in January 2008. ENHANCE found that the drug was no better than a cheaper, generic statin in preventing clogged arteries, and raised serious questions about … [Read more...]
Vytorin Named in Lawsuit
Vytorin Named in Another Lawsuit. Disputed (PEBTF) has filed suit against Merck & Co. and Schering-Plough, alleging that the companies charged too much for both Vytorin, and Zetia, another cholesterol drug, which is also a component of Vytorin. Vytorin, a combination of the statin Zocor (simvastatin) and Zetia, has been under … [Read more...]
Vytorin Probe Seeks Information
Vytorin Probe Seeks Information. Lawmakers investigating the cholesterol drug Vytorin have asked Merck and Schering-Plough for more information on the medication's clinical trials. According to Reuters, Rep. Henry Waxman (D-Calif), chairman of the House Energy and Commerce Committee, has written two companies on Thursday seeking … [Read more...]
Vytorin, Zetia Disappoint Again
Vytorin, Zetia Disappoint Vytorin and Zetia, Merck & Co.'s anti-cholesterol medications, are coming under fire again. A new study has found that a much older - and cheaper - drug reduced artery plaque much better in eight months than ezetimibe, the active ingredient in both Vytorin and Zetia. According to USA Today, this … [Read more...]
Experts Divided on Vytorin Cancer Risk
Vytorin Potential Cancer Risk. Vytorin was the subject of a heated debate at the annual meeting of the American Heart Association in New Orleans yesterday. At issue was the controversial drug's potential cancer risk. While some heart experts on a panel discussing the issue tried to ease concerns about Vytorin and cancer, others said … [Read more...]
New Haven to Sue Merck and Schering-Plough
Merck and Schering-Plough Lawsuit. The city of New Haven, Connecticut, is reporting that over $400,000 in tax dollars were spent on Vytorin and Zetia for employees. Now, corporation counsel John Ward is seeking return of that money over ongoing claims that Vitorin “doesn’t work” he said in an interview with The New Haven … [Read more...]
Vytorin Confusion Leaves Patients Wondering
Vytorin Confusion Leaves Patients Wondering. Many patients - and probably some doctors - are scratching their heads over Vytorin. Though it has been on the market for four years, little is known about its safety and effectiveness. This year, two studies - ENHANCE and SEAS - have only added to the confusion over the … [Read more...]
Vytorin Cancer Controversy Far from Over
Vytorin Cancer Controversy. News earlier this summer that Vytorin had been tied to a higher risk of cancer by a newly published study quickly faded from the headlines. Merck and Schering-Plough's reassurance that the cancer finding in the SEAS study was an anomaly apparently squashed much discussion of the issue - at least … [Read more...]
Vytorin – Cancer Link Draws Congressional Scrutiny
Vytorin May Cause Risk Of Cancer. Cancer Link Draws Congressional Scrutiny, Lawmakers on a congressional committee want to see the results of a new study that indicated patients taking Vytorin might be at a higher risk of cancer. That study, known as SEAS, was given to the Food & Drug Administration (FDA), but has yet to be … [Read more...]
Vytorin Makers Defend Drug
Vytorin Makers Defend Drug. Vytorin makers Merck and Schering-Plough are preparing to send a letter to thousands of physicians in an attempt to address cancer concerns raised by a recently published study. While the companies acknowledge that Vytorin users enrolled in the SEAS study had higher rates of cancer than those … [Read more...]
Another Vytorin Failure
Another Vytorin Failure. Yesterday's news that Vytorin failed to meet the primary endpoint in another important study has not done much to restore faith in the controversial cholesterol drug. First shown to be ineffective in preventing clogged arteries, it now seems Vytorin does little to help patients with aortic … [Read more...]
Vytorin Falls Short in Study, Cancer Link Found
Vytorin Falls Short in Another Study. Vytorin, the controversial cholester found that patients taking Vytorin in the study were more likely to develop cancer. Vytorin, which was developed and marketed jointly by Merck and Schering-Plough, was approved for use by the Food & Drug Administration (FDA) in 2004. Since it came on the … [Read more...]
Senator McCain Quit Vytorin After ENHANCE
Senator McCain Quit Vytorin. Many former Vytorin patients switched off the expensive drug after a study -called ENHANCE - released earlier this year showed it was no more effective than cheaper statins. Now it turns out that one of those patients was none other than Republican presidential nominee Senator John … [Read more...]
UnitedHealth Group Says it Will Still Cover Vytorin
UnitedHealth Group Still Cover Vytorin. Vytorin coverage will not change for people enrolled in health plans provided by UnitedHealth Group. The nation's largest health insurer said it will continue paying for Vytorin, even though a recently released study showed it worked no better than cheaper statin drugs. Many health insurers … [Read more...]
Insurers Taking Another Look at Vytorin Coverage
Vytorin Provided No Added Benefits. Insurers are said to be reconsidering coverage for Vytorin, after a study showed the cholesterol-lowering drug provided no added benefits over cheaper statins. Already, one large insurer has changed its approach to Vytorin coverage, and it is thought others will follow. Vytorin, which … [Read more...]
Vytorin Emails Raise Questions About ENHANCE Delay
Vytorin Emails Raise Questions The Vytorin fallout continues, with one lawmaker demanding that Vytorin's makers explain why the results of a crucial study were delayed for more than a year. The request for more information on the delayed Vytorin study came just a day after a panel of prominent cardiologists recommended that Vytorin … [Read more...]
Vytorin Probe Targets Message Board Posts
Vytorin Probe Message Board Posts. The Vytorin probe in Congress took another turn this week, with investigators seeking information on several posts left on internet message boards frequented by people working in the pharmaceutical industry. Vytorin, and its makers Merck and Schering-Plough, have been under … [Read more...]
Vytorin Lawsuits Keep Coming
Merck and Schering-Plough Vytorin Lawsuits. Vytorin makers Merck and Schering-Plough are facing yet another lawsuit, this time from the plaintiffs in Nevada. The Nevada Vytorin consumer fraud lawsuit alleges that Merck and Schering-Plough deceived heart patients in that state by leading them to believe that Vytorin was more effective … [Read more...]
Vytorin in Connecticut Crosshairs
Connecticut's Merck and Schering-Plough Vytorin Investigation. Connecticut can now be added to the list of states investigating Vytorin. According to The Wall Street Journal, Connecticut Attorney General Richard Blumenthal announced that his office investigating Merck and Schering-Plough for claims the companies made about … [Read more...]
FDA Issues Vytorin Early Communication
FDA Reviews Vytorin. The Food & Drug Administration (FDA) weighed in on the Vytorin controversy today by issuing an Early Communication about its ongoing reviews of Vytorin, Zetia and Zocor. The FDA communication was prompted by preliminary results of the ENHANCE study that showed Vytorin was no better at preventing plaque … [Read more...]
Vytorin Lawsuit Alleges Merck, Schering-Plough Knew Drug Was Ineffective
Vytorin Lawsuit Alleges Merck. The makers of Vytorin have been named as defendants in a lawsuit filed by a New York man who took the defective drug based on the belief that it offered more protection from clogged arteries, heart attacks and strokes than other, less expensive statin drugs. Sigmond Tomaszewski, who began … [Read more...]
